• CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib

    1 month ago - By Medscape

    The second-generation Bruton's tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia .
    MDedge News
    Read more ...